Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.23
- Piotroski Score 2.00
- Grade Buy
- Symbol (CABA)
- Company Cabaletta Bio, Inc.
- Price $1.89
- Changes Percentage (1.07%)
- Change $0.02
- Day Low $1.82
- Day High $1.99
- Year High $26.35
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/13/2025
- Fiscal Year End N/A
- Average Stock Price Target $14.00
- High Stock Price Target $32.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.71
- Trailing P/E Ratio -6.16
- Forward P/E Ratio -6.16
- P/E Growth -6.16
- Net Income $-67,675,000
Income Statement
Quarterly
Annual
Latest News of CABA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate
Investing in unprofitable businesses can be profitable, but there are risks. Analyzing Cabaletta Bio's cash burn and runway, despite a solid cash reserve, its increasing burn rate may raise concerns a...
By Yahoo! Finance | 3 weeks ago -
NYC bar owner claims James Caban tried to 'extort' him over NYPD...
Brooklyn bar owner, Shamel Kelly, claims that James Caban, the twin brother of ex-NYPD Commissioner Edward Caban, tried to extort $2,500 to resolve police issues. City Hall staffer Ray Martin facilita...
By New York Post | 2 months ago -
NYC Police Commissioner Edward Caban will step down, source says
New York City Police Commissioner Edward Caban to resign after federal raids on Mayor Eric Adams' inner circle. Investigations involve seized cellphones and alleged connections to nightclubs. No charg...
By CBS News | 2 months ago
